| Symbol | ONCY |
|---|---|
| Name | ONCOLYTICS BIOTECH INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 804, 322 - 11 AVENUE SW, CALGARY, None None |
| Telephone | 4036707377 |
| Fax | — |
| — | |
| Website | https://www.oncolyticsbiotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001129928 |
| Description | Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The companys product pipeline includes Bavencio, Keytruda, Retifanlimab, and Tecentriq. Additional info from NASDAQ: |
2026-06-16 13:05
(72% Positive) ONCOLYTICS BIOTECH INC (ONCY) Provides Update on process for pelareorep
Read more
2026-06-03 20:30
Director Pisano Wayne 🟢 acquired 30.0K shares (1 derivative) of ONCOLYTICS BIOTECH INC (ONCY) at $1.06 Transaction Date: Jun 01, 2026 | Filing ID: 027095
Read more
2026-06-03 20:30
Director RIGBY JONATHAN 🟢 acquired 30.0K shares (1 derivative) of ONCOLYTICS BIOTECH INC (ONCY) at $1.06 Transaction Date: Jun 01, 2026 | Filing ID: 027097
Read more
2026-06-03 20:30
Director Holtham Angela 🟢 acquired 30.0K shares (1 derivative) of ONCOLYTICS BIOTECH INC (ONCY) at $1.06 Transaction Date: Jun 01, 2026 | Filing ID: 027092
Read more
2026-06-03 20:30
Director Parsons James T. 🟢 acquired 30.0K shares (1 derivative) of ONCOLYTICS BIOTECH INC (ONCY) at $1.06 Transaction Date: Jun 01, 2026 | Filing ID: 027089
Read more
2026-06-03 20:30
Look Kirk 🟢 acquired 260.0K shares (1 derivative) of ONCOLYTICS BIOTECH INC (ONCY) at $1.06 Transaction Date: Jun 01, 2026 | Filing ID: 027091
Read more
2026-06-03 20:30
Aromando Andrew 🟢 acquired 260.0K shares (1 derivative) of ONCOLYTICS BIOTECH INC (ONCY) at $1.06 Transaction Date: Jun 01, 2026 | Filing ID: 027088
Read more
2026-06-03 20:30
Director Kelly Jared 🟢 acquired 755.0K shares (1 derivative) of ONCOLYTICS BIOTECH INC (ONCY) at $1.06 Transaction Date: Jun 01, 2026 | Filing ID: 027084
Read more
2026-06-03 20:30
Director Seizinger Bernd R. 🟢 acquired 30.0K shares (1 derivative) of ONCOLYTICS BIOTECH INC (ONCY) at $1.06 Transaction Date: Jun 01, 2026 | Filing ID: 027081
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07446322 | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of… | Phase2 | Ras-mutated Metastatic Colorectal Cancer | Recruiting | 2026-04-30 | 2030-04-30 | ClinicalTrials.gov |
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment … | Phase1 | Anal Cancer Metastatic | Active_Not_Recruiting | 2021-10-27 | 2028-12-31 | ClinicalTrials.gov |
| NCT04215146 | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype i… | Phase2 | Breast Cancer Metastatic | Active_Not_Recruiting | 2020-06-10 | 2025-06-01 | ClinicalTrials.gov |
| NCT04102618 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | Early_Phase1 | Breast Cancer | Terminated | 2019-03-29 | 2022-04-20 | ClinicalTrials.gov |
| NCT03015922 | Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma | Phase1 | Multiple Myeloma | Unknown | 2017-06-05 | 2021-10-01 | ClinicalTrials.gov |
| NCT02723838 | Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin a… | Phase1 | Muscle-invasive Transitional Cell Carcinoma of the Bladder | Withdrawn | 2017-02-28 | 2018-02-28 | ClinicalTrials.gov |
| NCT02620423 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advance… | Phase1 | Pancreatic Adenocarcinoma | Completed | 2015-12-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT02514382 | Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Rel… | Phase1 | Recurrent Plasma Cell Myeloma | Completed | 2015-08-21 | 2022-04-19 | ClinicalTrials.gov |
| NCT01656538 | A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer | Phase2 | Metastatic Breast Cancer | Completed | 2013-02-20 | 2018-02-14 | ClinicalTrials.gov |
| NCT01619813 | Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alo… | Phase2 | Prostate Cancer | Completed | 2012-12-14 | 2016-05-20 | ClinicalTrials.gov |
| NCT01708993 | Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer … | Phase2 | Non Small Cell Lung Cancer | Completed | 2012-12-10 | 2018-09-26 | ClinicalTrials.gov |
| NCT01622543 | Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab… | Phase2 | Colorectal Cancer | Completed | 2012-10-26 | 2018-09-12 | ClinicalTrials.gov |
| NCT01274624 | Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive… | Phase1 | KRAS Mutant Metastatic Colorectal Cancer | Completed | 2010-12-01 | 2018-11-01 | ClinicalTrials.gov |
| NCT01166542 | Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in P… | Phase3 | Carcinoma, Squamous Cell of the Head and Neck | Completed | 2010-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT00998322 | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced … | Phase2 | Metastatic Pancreatic Adenocarcinoma | Completed | 2009-10-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT00998192 | A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients… | Phase2 | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung | Completed | 2009-10-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT00984464 | Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients W… | Phase2 | Metastatic Melanoma | Completed | 2009-09-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT00861627 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for N… | Phase2 | Carcinoma, Non-small Cell Lung | Completed | 2009-03-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT00753038 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Pa… | Phase2 | Carcinoma, Squamous Cell of the Head and Neck | Completed | 2008-08-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00503295 | Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue… | Phase2 | Osteosarcoma | Completed | 2007-06-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00528684 | Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant … | Phase1 | Malignant Glioma | Completed | 2006-07-01 | 2010-06-01 | ClinicalTrials.gov |
Total clinical trials: 21
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Squamous Cell of the Head and Neck | COMPLETED | NCT01166542 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Squamous Cell of the Head and Neck | COMPLETED | NCT01166542 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Squamous Cell of the Head and Neck | COMPLETED | NCT01166542 |
| REOLYSIN | Other | Phase PHASE3 | Carcinoma, Squamous Cell of the Head and Neck | COMPLETED | NCT01166542 |
| Gemcitabine | Other | Phase PHASE2 | Metastatic Pancreatic Adenocarcinoma | COMPLETED | NCT00998322 |
| REOLYSIN | Other | Phase PHASE2 | Metastatic Pancreatic Adenocarcinoma | COMPLETED | NCT00998322 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | COMPLETED | NCT00984464 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Melanoma | COMPLETED | NCT00984464 |
| REOLYSIN | Other | Phase PHASE2 | Metastatic Melanoma | COMPLETED | NCT00984464 |
| Carboplatin | Other | Phase PHASE2 | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung | COMPLETED | NCT00998192 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung | COMPLETED | NCT00998192 |
| REOLYSIN | Other | Phase PHASE2 | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung | COMPLETED | NCT00998192 |
| Cisplatin | Other | Phase PHASE1 | Muscle-invasive Transitional Cell Carcinoma of the Bladder | WITHDRAWN | NCT02723838 |
| Gemcitabine | Other | Phase PHASE1 | Muscle-invasive Transitional Cell Carcinoma of the Bladder | WITHDRAWN | NCT02723838 |
| REOLYSIN® | Other | Phase PHASE1 | Muscle-invasive Transitional Cell Carcinoma of the Bladder | WITHDRAWN | NCT02723838 |
| Pembrolizumab | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| 5-fluorouracil | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| Leucovorin | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| Irinotecan | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| Chemotherapy | Drug | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| REOLYSIN® | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| Bevacizumab | Other | Phase PHASE1 | KRAS Mutant Metastatic Colorectal Cancer | COMPLETED | NCT01274624 |
| Fluorouracil (5-FU) | Other | Phase PHASE1 | KRAS Mutant Metastatic Colorectal Cancer | COMPLETED | NCT01274624 |
| Leucovorin | Other | Phase PHASE1 | KRAS Mutant Metastatic Colorectal Cancer | COMPLETED | NCT01274624 |
| Irinotecan | Other | Phase PHASE1 | KRAS Mutant Metastatic Colorectal Cancer | COMPLETED | NCT01274624 |
| REOLYSIN® | Other | Phase PHASE1 | KRAS Mutant Metastatic Colorectal Cancer | COMPLETED | NCT01274624 |
| REOLYSIN | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03015922 |
| Lenalidomide or Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03015922 |
| Trastuzumab | Other | Phase EARLY_PHASE1 | Breast Cancer | TERMINATED | NCT04102618 |
| Atezolizumab | Other | Phase EARLY_PHASE1 | Breast Cancer | TERMINATED | NCT04102618 |
| Letrozole | Other | Phase EARLY_PHASE1 | Breast Cancer | TERMINATED | NCT04102618 |
| Pelareorep | Other | Phase EARLY_PHASE1 | Breast Cancer | TERMINATED | NCT04102618 |
| Docetaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT01708993 |
| Docetaxel and Reolysin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT01708993 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT01708993 |
| Pemetrexed and Reolysin (and safety run-in) | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT01708993 |
| Reolysin | Other | Phase PHASE2 | Metastatic Breast Cancer | COMPLETED | NCT01656538 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Breast Cancer | COMPLETED | NCT01656538 |
| Docetaxel and Prednisone | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01619813 |
| Docetaxel, Reolysin and Prednisone | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01619813 |
| Wild-type Reovirus | Other | Phase PHASE1 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02514382 |
| Pharmacological Study | Other | Phase PHASE1 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02514382 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02514382 |
| Dexamethasone | Other | Phase PHASE1 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02514382 |
| Bortezomib | Other | Phase PHASE1 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02514382 |
| Folfox plus Bevacizumab | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT01622543 |
| Folfox plus Bevacizumab and reolysin | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT01622543 |
| Avelumab | Other | Phase PHASE2 | Breast Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT04215146 |
| Pelareorep | Other | Phase PHASE2 | Breast Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT04215146 |
| Paclitaxel | Other | Phase PHASE2 | Breast Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT04215146 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE1 | Anal Cancer Metastatic | RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | Other | Phase PHASE1 | Anal Cancer Metastatic | RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | Anal Cancer Metastatic | RECRUITING | NCT07280377 |
| Atezolizumab | Other | Phase PHASE1 | Anal Cancer Metastatic | RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE1 | Anal Cancer Metastatic | RECRUITING | NCT07280377 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Pelareorep | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| Bevacizumab | Other | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | RECRUITING | NCT07446322 |
| FOLFIRI | DRUG | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07446322 |
| mFOLFIRINOX Treatment Regimen | DRUG | Phase PHASE1 | Anal Cancer Metastatic | RECRUITING | NCT07280377 |
| Trifluridine Tipiracil | DRUG | Phase PHASE1 | Anal Cancer Metastatic | RECRUITING | NCT07280377 |
| Gemcitabine and nab-paclitaxel | DRUG | Phase PHASE1 | Anal Cancer Metastatic | RECRUITING | NCT07280377 |
| Avelumab | DRUG | Phase PHASE2 | Breast Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT04215146 |
| Trastuzumab | DRUG | Phase EARLY_PHASE1 | Breast Cancer | TERMINATED | NCT04102618 |
| Atezolizumab | DRUG | Phase PHASE1 | Anal Cancer Metastatic | RECRUITING | NCT07280377 |
| Letrozole | DRUG | Phase EARLY_PHASE1 | Breast Cancer | TERMINATED | NCT04102618 |
| Pelareorep | DRUG | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07446322 |
| Lenalidomide or Pomalidomide | DRUG | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03015922 |
| Cisplatin | DRUG | Phase PHASE1 | Muscle-invasive Transitional Cell Carcinoma of the Bladder | WITHDRAWN | NCT02723838 |
| Pembrolizumab | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| 5-fluorouracil | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| Chemotherapy | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| Wild-type Reovirus | BIOLOGICAL | Phase PHASE1 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02514382 |
| Pharmacological Study | OTHER | Phase PHASE1 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02514382 |
| Laboratory Biomarker Analysis | OTHER | Phase PHASE1 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02514382 |
| Dexamethasone | DRUG | Phase PHASE1 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02514382 |
| Bortezomib | DRUG | Phase PHASE1 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02514382 |
| Docetaxel | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT01708993 |
| Docetaxel and Reolysin | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT01708993 |
| Pemetrexed | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT01708993 |
| Pemetrexed and Reolysin (and safety run-in) | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT01708993 |
| Reolysin | DRUG | Phase PHASE2 | Metastatic Breast Cancer | COMPLETED | NCT01656538 |
| Folfox plus Bevacizumab | DRUG | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT01622543 |
| Folfox plus Bevacizumab and reolysin | DRUG | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT01622543 |
| Docetaxel and Prednisone | DRUG | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01619813 |
| Docetaxel, Reolysin and Prednisone | DRUG | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01619813 |
| Bevacizumab | DRUG | Phase PHASE2 | Ras-mutated Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07446322 |
| Fluorouracil (5-FU) | DRUG | Phase PHASE1 | KRAS Mutant Metastatic Colorectal Cancer | COMPLETED | NCT01274624 |
| Leucovorin | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| Irinotecan | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02620423 |
| Placebo | DRUG | Phase PHASE3 | Carcinoma, Squamous Cell of the Head and Neck | COMPLETED | NCT01166542 |
| Gemcitabine | DRUG | Phase PHASE1 | Muscle-invasive Transitional Cell Carcinoma of the Bladder | WITHDRAWN | NCT02723838 |
| REOLYSIN | BIOLOGICAL | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT03015922 |
| Paclitaxel | DRUG | Phase PHASE2 | Breast Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT04215146 |
| Carboplatin | DRUG | Phase PHASE3 | Carcinoma, Squamous Cell of the Head and Neck | COMPLETED | NCT01166542 |
| REOLYSIN® | BIOLOGICAL | Phase PHASE1 | Muscle-invasive Transitional Cell Carcinoma of the Bladder | WITHDRAWN | NCT02723838 |
Total products: 261